Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 High-dose statins in acute coronary syndromes: not just lipid levels.

Literature DB >> 15337731

High-dose statins in acute coronary syndromes: not just lipid levels.

Steven E Nissen.

Abstract

Entities: Chemical

Mesh：

Substances：

Year: 2004 PMID： 15337731 DOI： 10.1001/jama.292.11.1365

Source DB: PubMed Journal: JAMA ISSN： 0098-7484 Impact factor: 56.272

Keyword Cloud
Cited

× No keyword cloud information.

18 in total

Review 1. Regulation of different inflammatory diseases by impacting the mevalonate pathway.

Authors: Robert Zeiser; Kristina Maas; Sawsan Youssef; Christoph Dürr; Lawrence Steinman; Robert S Negrin
Journal: Immunology Date: 2009-05 Impact factor: 7.397

Review 2. Treatment of multiple-risk patients: using combination therapy to treat beyond LDL lowering.

Authors: Howard S Weintraub
Journal: Curr Hypertens Rep Date: 2005-08 Impact factor: 5.369

3. N-3 fatty acid supplementation to routine statin treatment inhibits platelet function, decreases patients' daytime blood pressure, and improves inflammatory status.

Authors: Keren Doenyas-Barak; Sylvia Berman; Ramzia Abu-Hamad; Ahuva Golik; Naomi Rahimi-Levene; Shai Efrati
Journal: Eur J Clin Pharmacol Date: 2012-02-25 Impact factor: 2.953

4. Simvastatin as a treatment for pulmonary hypertension trial.

Authors: Martin R Wilkins; Omar Ali; William Bradlow; John Wharton; Anne Taegtmeyer; Christopher J Rhodes; Hossein A Ghofrani; Luke Howard; Petros Nihoyannopoulos; Raad H Mohiaddin; J Simon R Gibbs
Journal: Am J Respir Crit Care Med Date: 2010-05-15 Impact factor: 21.405

5. Treatment with pravastatin and fenofibrate improves atherogenic lipid profiles but not inflammatory markers in ACTG 5087.

Authors: Carl J Fichtenbaum; Tzu-Min Yeh; Scott R Evans; Judith A Aberg
Journal: J Clin Lipidol Date: 2010 Jul-Aug Impact factor: 4.766

Review 6. Secondary prevention of coronary heart disease in elderly patients following myocardial infarction: are all HMG-CoA reductase inhibitors alike?

Authors: Bijesh P Maroo; Carl J Lavie; Richard V Milani
Journal: Drugs Aging Date: 2008 Impact factor: 3.923

High-dose statins in acute coronary syndromes: not just lipid levels.

Review 1. Regulation of different inflammatory diseases by impacting the mevalonate pathway.

Review 2. Treatment of multiple-risk patients: using combination therapy to treat beyond LDL lowering.

3. N-3 fatty acid supplementation to routine statin treatment inhibits platelet function, decreases patients' daytime blood pressure, and improves inflammatory status.

4. Simvastatin as a treatment for pulmonary hypertension trial.

5. Treatment with pravastatin and fenofibrate improves atherogenic lipid profiles but not inflammatory markers in ACTG 5087.

Review 6. Secondary prevention of coronary heart disease in elderly patients following myocardial infarction: are all HMG-CoA reductase inhibitors alike?

Review 7. PROVE-IT proves that lower is better: a contrary view.

Review 8. Novel targets and new potential: developments in the treatment of inflammation in chronic kidney disease.

Review 9. Atorvastatin efficacy in the primary and secondary prevention of cardiovascular events.

Review 10. Effects of atorvastatin on the different phases of atherogenesis.